Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Bevurogant (BI 730357) in Moderate-to-Severe Plaque Psoriasis
NCT03635099Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2018
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of bevurogant in plaque psoriasis, sponsored by Boehringer Ingelheim. Started Sep 2018; status: completed.
02
Drugs
bevurogant
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03635099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03635099.